Treatment of Xenografted Ovarian Carcinoma Using Paclitaxel-loaded Ultrasound Microbubbles

Academic Radiology

Volumn 15, Issue 12, 2008, Pages 1574-1579

  Xing, Wu ^a   Gang, Wang Z ^a   Yong, Zhang ^a   Yi, Zheng Y ^a   Shan, Xu C ^a   Tao, Ran H ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

drug loaded microbubbles; ovarian carcinoma; paclitaxel; Ultrasound

Indexed keywords

PACLITAXEL; PROTEIN P53; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG RELEASE; FEMALE; IMMUNOHISTOLOGY; MICROBUBBLE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; ULTRASOUND; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; MICE; MICE, NUDE; MICROBUBBLES; OVARIAN NEOPLASMS; PACLITAXEL; SONICATION; TREATMENT OUTCOME;

EID: 55349116419     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2008.06.013     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Ozols R.F. Challenges for chemotherapy in ovarian cancer. Ann Oncol 17 suppl (2006) 181-187
3. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62 (1978) 1-11
4. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89 (1997) 480-487
5. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
6. Rothenberg M.L., Liu P.Y., Braly P.S., et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21 (2003) 1313-1319
7. Tiukinhoy S.D., Mahowald M.E., Shively V.P., et al. Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery. Invest Radiol 35 (2000) 732-738
8. Li T., Tachibana K., Kuroki M., and Kuroki M. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice-initial results. Radiology 229 (2003) 423-428
9. Amura M., Sato N., Taniyama Y., et al. Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound. Gene Ther 11 (2004) 1532-1539
10. Zhigang W., Zhiyu L., Haitao R., et al. Ultrasound-mediated microbubble destruction enhances VEGF gene delivery to the infarcted myocardium in rats. Clin Imaging 28 (2004) 395-398
11. Zhang Q., Wang Z., Ran H., et al. Enhanced gene delivery into skeletal muscles with ultrasound and microbubble techniques. Acad Radiol 13 (2006) 363-367
12. Yang C., Wang Z., Li X., et al. Preparation of acoustically active lipospheres containing paclitaxel. Chinese J Ultrasonogr 15 (2006) 535-538
13. Yang C., Wang Z., Lai T., Li P., Peng X., and Xie Z. Study on cytotoxic effect and acute toxicity of self-made paclitaxel-carrying lipospheres. Chinese J Ultrasound Med 22 (2006) 481-483
14. Mitragotri S., Blankschtein D., and Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharmaceut Res 13 (1996) 411-420
15. Mitragotri S., and Kost J. Low-frequency sonophoresis: a noninvasive method of drug delivery and diagnostics. Biotechnol Prog 16 (2000) 488-492
16. Tachibana K., Uchida T., Tamura K., Eguchi H., Yamashita N., and Ogawa K. Enhanced cytotoxic effect of Ara-C by low intensity ultrasound to HL-60 cells. Cancer Lett 149 (2000) 189-194
17. Munshi N., Rapoport N., and Pitt W.G. Ultrasonic activated drug delivery from Pluronic P-105 micelles. Cancer Lett 117 (1997) 1-7
18. Yu T.H., Hu K., Bai J., and Wang Z.B. Reversal of adriamycin resistance in ovarian carcinoma cell line by combination of verapamil and low-level ultrasound. Ultrason Sonochemy 10 (2003) 37-40
19. Marmottant P., and Hilgenfeldt S. Controlled vesicle deformation and lysis by single oscillating bubbles. Nature 423 (2003) 153-156
20. Hernot S., and Klibanov A.L. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 60 (2008) 1153-1166
21. Park S.I., Shah A.N., Zhang J., et al. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Exp Opin Ther Targets 11 (2007) 1207-1217
22. Lee J.S., Choi Y.D., Lee J.H., et al. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer 16 suppl (2006) 247-253
23. Loo W.T., Fong J.H., Cheung M.N., and Chow L.W. The efficacy of paclitaxel on solid tumour analysed by ATP bioluminescence assay and VEGF expression: a translational research study. Biomed Pharmacother 59 suppl (2005) S337-S339
24. Niu Q., Tang Z.Y., Ma Z.C., et al. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 6 (2000) 565-568
25. Ueno Y. Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho 109 (2006) 163-170
26. Inan S., Vatansever S., Celik-Ozenci C., et al. Immunolocalizations of VEGF, its receptors flt-1, KDR, and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21 (2006) 1055-1064
27. Kim S.Y., Kim J.Y., Kim S.H., et al. Surfactin from Bacillus subtilis displays anti-proliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppression. FEBS Lett 581 (2007) 865-871
28. Secord A.A., Darcy K.M., Hutson A., et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 106 (2007) 221-232